pharmaphorum

JULY 28, 2021

Continuing orders for Pfizer’s BioNTech-partnered COVID-19 vaccine Comirnaty have prompted near one-third increase in its projected revenues for the vaccine this year, from $26 billion to $33.5 billion in direct sales and alliance revenues – helped Pfizer’s total second-quarter almost double to just below $19 billion.

Sales 52

Sales Vaccination Vaccine Trials 52

Pharmaceutical Technology

FEBRUARY 8, 2023

The 13 top players experienced significant growth over 2022 despite the decline in demand for COVID-19 vaccines and therapeutics, as well as uncertainty surrounding pricing due to the newly passed Inflation Reduction Act in the US. billion between Dec 31, 2021 and Dec 31, 2022, owing to expansion in its vaccine and oncology portfolio.

Marketing 195

Marketing Sales Vaccination Vaccine 195

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 billion takeover of Tesaro in 2019.

Sales 89

Sales Vaccination Vaccine Drugs 89

XTalks

FEBRUARY 5, 2024

In the first year of the respiratory syncytial virus (RSV) vaccine battle, GlaxoSmithKline’s (GSK) Arexvy emerged as the winner over Pfizer’s Abrysvo. GSK declared Arexvy to be a blockbuster in its first year on the market after higher-than-expected sales. The company has reported the vaccine to be 83.7 billion or £1.2

Vaccination 59

Vaccination Vaccine Marketing Sales 59

Pharmaceutical Technology

MAY 30, 2023

Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Lecanemab leads the charge with projected sales of $4.67bn in 2028, 529% more than its closest competitor, Gammagard by Takeda.

Drugs 264

Drugs Sales Antibody Dermatology 264

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. over the last five years. A broad front.

Vaccination 132

Vaccination Vaccine Clinical Trials Clinical Trials 132

Roots Analysis

OCTOBER 25, 2023

On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. According to Roots Analysis, the antibody drug conjugate market is estimated to be worth $7.72

Antibody 40

Antibody Development Drugs Marketing 40

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

pharmaphorum

SEPTEMBER 27, 2022

The emergence of PD-(L1) treatments has provided patients options where previously none existed, and the leading forms of these therapies have gone on to blockbuster sales. One area that is becoming more widely discussed with the potential to be added to this group is that of therapeutic cancer vaccines. billion.

Vaccination 92

Vaccination Vaccine Trials Clinical Trials 92

World of DTC Marketing

APRIL 11, 2021

QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Based on the virus a number of vaccines targeting the spike protein were designed, tested in animal models and found to be quite promising against SARS and other coronavirus illnesses like Middle East respiratory syndrome.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

pharmaphorum

NOVEMBER 12, 2021

AstraZeneca has said it plans to start making a small profit from sales of its COVID-19 vaccine Vaxzevria, which brought in just over $1 billion in sales in the third quarter, after selling it at cost since it was first made available. Overall, AZ had a strong third quarter with sales up 48% to $9.9

Vaccination 52

Vaccination Vaccine Sales Licensing 52

pharmaphorum

MARCH 30, 2022

CureVac and GlaxoSmithKline’s first attempt to develop a COVID-19 vaccine was a salutary reminder of the pitfalls in drug development, as the mRNA shot crashed and burned in a clinical trial last year, but they aren’t giving up. ” The post CureVac and GSK try again with COVID-19 vaccine appeared first on. .

Vaccination 64

Vaccination Vaccine Protein Antibody 64

pharmaphorum

JANUARY 27, 2023

AstraZeneca’s revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against most subvariants now circulating in the US. In fact, Evusheld is following the same trajectory as other COVID-19 antibodies.

Antibody 135

Antibody Sales Clinical Trials Clinical Trials 135

pharmaphorum

OCTOBER 30, 2020

Moderna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go to plan – but has already received $1.1 That is the basis for filing for emergency use authorisation (EUA) of the vaccine in the US, according to criteria set out by the FDA. billion in deposits for the shot.

Vaccination 88

Vaccination Vaccine Sales Trials 88

pharmaphorum

FEBRUARY 10, 2022

AstraZeneca confirmed today that it has discontinued clinical development of a follow-up to its COVID-19 vaccine Vaxzevria targeted at the Beta variant of the virus, which started development before the emergence of the Delta and Omicron strains. The post AZ halts development of Beta variant COVID-19 vaccine appeared first on.

Vaccination 52

Vaccination Vaccine Development Immune Response 52

XTalks

MAY 29, 2024

Products like electrophysiology devices, contact lenses and surgical products were major drivers of sales in this area. In its acquisitions, J&J also acquired antibody-drug conjugate (ADC) developer Ambryx and cardiac med tech Laminar along with more than 50 smaller, early-stage licensing deals and partnerships.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccination 52

XTalks

DECEMBER 3, 2021

As Omicron continues to be closely watched around the world with more information awaited from researchers, COVID-19 vaccine makers Pfizer and Moderna announced they’re getting to work on a booster for the newest COVID-19 variant of concern (VOC). As such, the country has led in identifying variants and in trials for COVID-19 vaccines.

Vaccination 98

Vaccination Vaccine Trials Sales 98

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. The EU says its advance purchase order will finance part of the upfront costs of developing the vaccine.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

pharmaphorum

FEBRUARY 14, 2022

Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental shingles vaccines CRV-101 and GlaxoSmithKline’s market-leading Shingrix. billion in sales last year, slightly down as a result of the pandemic.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

Pharmaceutical Technology

JUNE 6, 2023

Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). Moderna Overview Moderna is a biotechnology company that focuses on the development of messenger RNA therapeutics and vaccines.

RNA 100

RNA Protein Antibody Vaccination 100

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies.

Marketing 264

Marketing Vaccination Vaccine Development 264

pharmaphorum

AUGUST 7, 2020

Pharma’s reputation has soared due to the COVID-19 pandemic – but coronavirus is starting to bite companies’ sales. The US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 vaccine development initiative, committing up to $2.1

Sales 105

Sales Antibody Vaccination Vaccine 105

pharmaphorum

AUGUST 15, 2022

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna’s mRNA-1273.214 shot. 5 found that it stimulated a greater than five-fold increase in neutralising antibodies against Omicron BA.4 1 subvariant. 1 subvariant.

Vaccination 111

Vaccination Vaccine Antibody Regulation 111

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

The Pharma Data

AUGUST 10, 2020

Novavax is partnering up with the Serum Institute of India Private Limited (SIIPL) in a licensing deal to development and marketing of up to one billion doses of its potential recombinant COVID-19 vaccine candidate, NVX?CoV2373. Negotiations are currently ongoing to have SIIPL manufacture the candidate within India. M adjuvant. Matt Fellows.

Vaccination 52

Vaccination Vaccine Licensing Licensing 52

Delveinsight

AUGUST 26, 2021

Under the agreement, Shape is eligible to receive an initial payment and payments for hitting development, regulatory and sales milestones potentially exceeding USD 3 billion in aggregate value. BlueWillow Biologics announces positive interim results from Phase 1 Trial of Intranasal Anthrax Vaccine.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing.

Marketing 110

Marketing Sales Gene Editing Antibody 110

Pharmaceutical Technology

SEPTEMBER 15, 2022

The increase in the production of biological drugs such as vaccines, gene and cell therapies, and monoclonal antibodies, is increasing the volume of injectable drug products in the global healthcare market.

Marketing 130

Marketing Containment Production Sales 130

pharmaphorum

OCTOBER 27, 2021

GlaxoSmithKline said today it would halt further development of its antibody for severe COVID-19 pneumonia – otilimab – in order to focus its resources on Xevudy for mild-to-moderate disease. The news came as GSK reported a 5% increase in prescription drug sales to £4.4 HIV sales managed only a modest 3% gain to £1.3

Drugs 59

Drugs Sales Antibody Vaccination 59

pharmaphorum

OCTOBER 20, 2021

Johnson & Johnson has been offering its COVID-19 vaccine for sale on a no-profit basis since it became available, but is thinking about a possible switch to a standard commercial model next year or in 2023. S vaccine for the three-month period. S vaccine for the three-month period. billion.

Sales 52

Sales Vaccination Vaccine Marketing 52

pharmaphorum

NOVEMBER 11, 2022

For all their long history in vaccines, GSK and Sanofi have struggled to get a shot for COVID-19 authorised – but they have finally crossed the finish line in Europe. In those studies, VidPrevtyn Beta was found to trigger a higher production of antibodies against the Omicron BA.1 times more neutralising antibodies against Omicron BA.1

Vaccination 52

Vaccination Vaccine Antibody Sales 52

pharmaphorum

AUGUST 3, 2022

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter.

Sales 104

Sales Hormones Drugs Antibody 104

pharmaphorum

DECEMBER 2, 2021

The UK medicines regulator has approved GlaxoSmithKline and Vir Biotech’s antibody for COVID-19, Xevudy, which has been shown to be effective against the new Omicron strain of SARS-CoV-2 in lab testing. The antibody was found to reduce the risk of hospitalisation and death by 79% in this patient group in a clinical trial.

Antibody 119

Antibody Regulation Clinical Trials Clinical Trials 119

XTalks

MAY 2, 2024

The firm predicts sales of KarXT could reach $2.8 Current drugs on the market for schizophrenia include Lundbeck and Otsuka’s Rexulti (brexpiprazole) and Eli Lilly’s Prozac (fluoxetine), but these drugs derive the majority of their sales from other conditions, including severe forms of depression or Alzheimer’s agitation.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

Delveinsight

JANUARY 12, 2021

It is an IgM antibody targeting Death Receptor 5 (DR5), and IGM is hoping to test Birinapant with IGM-8444 for the treatment of solid cancers later this year. AvantGen Enters into a Licensing Agreement for its Anti-SARS-CoV-2 Antibodies with IGM Biosciences. million after Birinapant successfully becomes a part of the Phase I trials.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. An AbbVie antibody called ABBV-0805 successfully cleared a phase 1 trial but seems to have been shelved.

Antibody 95

Antibody Drugs Protein Licensing 95

Drug Discovery World

FEBRUARY 1, 2024

It will be presented by Phil Tuckett, BS, RM(NRCM, Department Scientist, Nelson Laboratories and Michelle Thai, Technical Sales Specialist, Pharma Analytics BioProduction Group, Thermo Fisher Scientific. This event will examine focused environmental monitoring within a cGMP facility.

Manufacturing 52

Manufacturing Genotype Gene Therapy Compliance 52